[{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Deep Apple Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Deep Apple Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Deep Apple Therapeutics \/ Apple Tree Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Deep Apple Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The net proceeds will be used for advancing multiple novel small molecule therapeutics focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Discovery

                          Sponsor : Apple Tree Partners

                          Deal Size : $52.0 million

                          Deal Type : Series A Financing

                          blank